Art

J-GLOBAL ID：202002234139687240   Reference number：20A0365153

Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice

DPP-4阻害剤,ビルダグリプチンは非糖尿病アポリポ蛋白質E欠損マウスにおいて内皮機能障害と粥腫発生を減弱する

Author (10)： Aini Kunduziayi (Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences) ,  Fukuda Daiju (Department of Cardio-Diabetes Medicine, Tokushima University Graduate School of Biomedical Science) ,  Tanaka Kimie (Division for Health Service Promotion, The University of Tokyo) ,  Higashikuni Yasutomi (Department of Cardiovascular Medicine, The University of Tokyo) ,  Hirata Yoichiro (Department of Pediatrics, The University of Tokyo Hospital) ,  Yagi Shusuke (Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences) ,  Kusunose Kenya (Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences) ,  Yamada Hirotsugu (Department of Community Medicine for Cardiology, Tokushima University Graduate School of Biomedical Sciences) ,  Soeki Takeshi (Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences) ,  Sata Masataka (Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences)
Material： International Heart Journal (Web)
Volume： 60  Issue： 6  Page： 1421-1429(J-STAGE)  Publication year： 2019 
JST Material Number： U1357A  ISSN： 1349-3299  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： knockout mouse ,...
Semi thesaurus term： *DPP-IV inhibitor ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0365153&from=J-GLOBAL&jstjournalNo=U1357A") }}

Author keywords (4)： Diabetes mellitus ,  Endothelial function ,  Atherosclerosis ,  GLP-1

JST classification (1)： Basic research of vasoactive drugs and hypotensive drugs  (GW07040J)

Substance index (1)： Vildagliptin

Reference (49)：

• 1. Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011; 13: 302-12.
• 2. Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol 2012; 109: 1681-5.
• 3. Ishizue N, Niwano S, Niwano H, et al. Linagliptin suppresses electrical and structural remodeling in the isoproterenol induced myocardial injury model. Int Heart J 2019; 60: 411-8.
• 4. Takahashi A, Ihara M, Yamazaki S, Asanuma H, Asakura M, Kitakaze M. Impact of either GLP-1 agonists or DPP-4 inhibitors on pathophysiology of heart failure. Int Heart J 2015; 56: 372-6.
• 5. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013; 62: 3316-23.

Terms in the title (9)： DPP-4阻害剤 ,  ビルダグリプチン ,  糖尿病 ,  アポリポ蛋白質E ,  欠損 ,  マウス ,  内皮機能障害 ,  粥腫発生 ,  減弱